Managers / Q2 2023 · view latest →
MPM ASSET MANAGEMENT LLC
CIK 0001263048 · 399 BOYLSTON STREET, SUITE 1100, BOSTON, MA, 02116 · 6174259200
Summary
Mpm Asset Management LLC reported $204M in U.S.-listed holdings across 8 positions for Q2 2023.
The portfolio is heavily concentrated: TRDA alone accounts for 32.9% of reported value.
Compared with Q1 2023, the fund opened 1 new position and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 96.0% · $196M
- ADR · 2.9% · $6M
- Other · 1.1% · $2M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| ADAPYAdaptimmune Therapeutics plc | NEW | +6.29M | 6.29M | +$6M | $6M |
| Amryt Pharma plc | SOLD OUT | −2.67M | 0 | −$39M | $0 |
| TCR2 Therapeutics, Inc. | SOLD OUT | −4.05M | 0 | −$6M | $0 |
| TRDAEntrada Therapeutics, Inc. | HELD | +0 | 4.43M | +$3M | $67M |
| HOWLWerewolf Therapeutics, Inc. | HELD | +0 | 4.28M | +$2M | $13M |
| RPTXRepare Therapeutics, Inc. | HELD | +0 | 2.24M | +$2M | $24M |
| DYNDyne Therapeutics, Inc. | HELD | +0 | 4.95M | −$1M | $56M |
| iTeos Therapeutics, Inc. | HELD | +0 | 2.74M | −$1M | $36M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2023
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | TRDAEntrada Therapeutics, Inc.history → | Common | 32.86% | $67M | 4.43M |
| 2 | DYNDyne Therapeutics, Inc.history → | Common | 27.32% | $56M | 4.95M |
| 3 | iTeos Therapeutics, Inc. | Common | 17.78% | $36M | 2.74M |
| 4 | RPTXRepare Therapeutics, Inc.history → | Common | 11.64% | $24M | 2.24M |
| 5 | HOWLWerewolf Therapeutics, Inc.history → | Common | 6.41% | $13M | 4.28M |
| 6 | ADAPYAdaptimmune Therapeutics plchistory → | Common | 2.85% | $6M | 6.29M |
| 7 | Harpoon Therapeutics, Inc. | Common | 1.09% | $2M | 3.13M |
| 8 | Oncorus, Inc. | Common | 0.06% | $115,403 | 2.85M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $45M | 4 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $43M | 5 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $69M | 6 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $124M | 6 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $145M | 6 | Nov 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $182M | 6 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $245M | 6 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $204M | 7 | Feb 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $187M | 7 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $204M | 8 | Sep 7, 2023 | RESTATEMENT | changes · EDGAR ↗ |
| Q1 2023 | $240M | 9 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $239M | 9 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $263M | 9 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $237M | 10 | Aug 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $293M | 10 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $463M | 10 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $431M | 9 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $538M | 9 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $518M | 8 | May 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $707M | 8 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $536M | 8 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $336M | 6 | Aug 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $164M | 5 | May 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $227M | 5 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $234M | 5 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $247M | 5 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $243M | 7 | May 29, 2019 | RESTATEMENT | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.